Vaxcyte Files 8-K: Other Events & Exhibits
Ticker: PCVX · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $103.00, $102.999, $98.1075, $98.1065 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-event
TL;DR
Vaxcyte filed an 8-K on 9/4, reporting 'Other Events' and financial exhibits. Details TBD.
AI Summary
Vaxcyte, Inc. filed an 8-K on September 6, 2024, reporting an "Other Event" and "Financial Statements and Exhibits" as of September 4, 2024. The filing does not contain specific details about the nature of the event or financial information within the provided text.
Why It Matters
This 8-K filing indicates that Vaxcyte has reported significant events or updated financial information, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material disclosures that would immediately indicate high risk.
Key Numbers
- 001-39323 — SEC File Number (Identifies Vaxcyte's filing with the SEC)
- 46-4233385 — IRS Employer Identification No. (Tax identification for Vaxcyte)
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- SutroVax, Inc. (company) — Former company name
- September 4, 2024 (date) — Date of earliest event reported
- September 6, 2024 (date) — Filing date
- 825 Industrial Road Suite 300 San Carlos, California 94070 (address) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Vaxcyte, Inc. in this 8-K filing?
The provided text does not specify the details of the 'Other Events' reported by Vaxcyte, Inc.
What are the key financial statements or exhibits included with this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific content is not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 4, 2024.
What is Vaxcyte, Inc.'s principal executive office address?
Vaxcyte, Inc.'s principal executive office is located at 825 Industrial Road, Suite 300, San Carlos, California 94070.
Has Vaxcyte, Inc. undergone a name change previously?
Yes, Vaxcyte, Inc. was formerly known as SutroVax, Inc., with a name change occurring on July 24, 2015.
Filing Stats: 923 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-09-06 08:00:33
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq
- $103.00 — per share, at a price to the public of $103.00 per share, and pre-funded warrants to p
- $102.999 — ommon stock at a price to the public of $102.999 per pre-funded warrant, which is the pr
- $98.1075 — common stock from Vaxcyte at a price of $98.1075 per share and the pre-funded warrants a
- $98.1065 — d the pre-funded warrants at a price of $98.1065 per pre-funded warrant. Vaxcyte also gr
- $1.42 b — se additional shares, is expected to be $1.42 billion, after deducting underwriting dis
Filing Documents
- d802914d8k.htm (8-K) — 31KB
- d802914dex11.htm (EX-1.1) — 222KB
- d802914dex41.htm (EX-4.1) — 66KB
- d802914dex51.htm (EX-5.1) — 26KB
- 0001193125-24-214711.txt ( ) — 548KB
- pcvx-20240904.xsd (EX-101.SCH) — 2KB
- pcvx-20240904_lab.xml (EX-101.LAB) — 18KB
- pcvx-20240904_pre.xml (EX-101.PRE) — 11KB
- d802914d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 1.1 Underwriting Agreement, dated September 4, 2024 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Skadden, Arps, Slate, Meagher & Flom LLP 23.1 Consent of Skadden, Arps, Slate, Meagher & Flom LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: September 6, 2024 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer